Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0500 |
Ask | 0.2500 |
Strike | 10.00 |
Expiry date | 2024-10-18 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 105 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Of